AOD-9604 vs Semaglutide
Side-by-side comparison of AOD-9604, Semaglutide — mechanism, dosing, half-life, side effects, and research status.
| Attribute | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss | Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | hGH C-terminal Fragment | GLP-1 Receptor Agonist |
| Amino acids | 16 | 31 |
| Molecular weight | 1,815.1 Da | 4,113.6 Da |
| Half-life | ~30 min | ~7 days |
| Route(s) | Subcutaneous, Oral (research) | Subcutaneous injection, Oral (Rybelsus) |
| Mechanism & Research | ||
| Primary mechanism | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… | Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… |
| Research status | Research Compound | FDA Approved |
| Evidence summary | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… | Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… |
| Protocol & Dosing | ||
| Typical dose | 300–500 mcg/day | 0.25mg → 2.4mg weekly (weight management) |
| Frequency | Once daily | Once weekly |
| Duration | 8–12 weeks | Ongoing (chronic management) |
| Timing | Pre-workout or morning on empty stomach (for metabolic effects) | Same day each week, any time |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Not Prohibited |
| Deeper reading | ||
| Related peptides | Semaglutide, Ipamorelin, Tesamorelin | Tirzepatide, AOD-9604, Tesamorelin |
| Full profile | Read full AOD-9604 profile → | Read full Semaglutide profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.